{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020847","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.824722+00:00","generated_at":"2026-06-15T04:37:41.831447+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyne Therapeutics Q1 net loss $44.2M; on track for initial trial data H2 2023","bullets":["Net loss $44.2M ($0.78/share) vs $35.6M ($0.69) in Q1 2022.","Cash $238.2M at March 31; raised $24.2M via ATM after quarter; funds through 2024.","R&D expenses $37.5M, up from $28.2M YoY.","Enrollment continues in ACHIEVE (DM1) and DELIVER (DMD) trials; initial data expected H2 2023.","DYNE-251 granted orphan drug and rare pediatric disease designations by FDA in March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020847","json":"https://secwatch.observer/filing/0000950170-23-020847.json","markdown":"https://secwatch.observer/filing/0000950170-23-020847.md","text":"https://secwatch.observer/filing/0000950170-23-020847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/0000950170-23-020847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/dyn-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:37:41.831447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2af5d3fb19c69da584eb6f9a52c96218ce08c3a","claim":"Dyne Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share., EPS $0.78 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/0000950170-23-020847-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share."},{"label":"EPS","value":"$0.78 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}